Top 5 This Week

Related Posts

Brent crude falls below $100 a barrel amid Middle East peace hopes – business live | Business

Brent crude falls 9% through $100 a barrel amid peace hopes

Brent crude futures have fallen below $100 a barrel!

The global benchmark is trading 9.2% lower at $99.79 a barrel.

Safe transit through the strait of Hormuz will be ensured with US threats coming to an end and new procedures in place, the Revolutionary Guards’ navy said on Wednesday, according to state media, in Iran’s first reaction to the US pausing operations to help stranded ships pass through the strait.

The Guards’ statement did not specify what the new procedures entailed, and thanked owners and captains of ships for respecting Iranian regulations when moving through the waterway.

As reported earlier, there are fresh hopes of an end to US-Israeli-war with Iran.

The US believes it is getting close to an agreement with Iran on a one-page memorandum of understanding to end the war, according to the American news website Axios, citing two US officials and two other sources briefed on the issue.

Axios also reported that both sides have set a framework for more detailed negotiations on Iran’s nuclear programme, a key issue at the heart of deadlocked talks between Washington and Tehran.

More on our our Middle East live blog:

Share

Updated at 

Key events

Novo shares jump after it reports surging demand for Wegovy pill

Wegovy maker Novo Nordisk said surging demand for its new weight loss pill means it will beat forecasts, sending its shares soaring.

The Copenhagen-listed share price jumped 6.6%, but is down 7.7% so far this year.

The Danish company, once the poster-child for the growth in weight-loss treatments, has been pinning its hopes on the Wegovy pill, launched in January, as it tries to recover lost ground in its battle with Mounjaro manufacturer Eli Lilly.

Struggling against competition from Lilly and generic drugmakers, Novo issued several profit warnings in recent months, the last one in February, and cut thousands of jobs last year.

Today, it said the Wegovy pill’s launch was the strongest of any obesity drug in the US. It expects the tablet to launch in other countries later this year.

The company reported more than two million prescriptions of the pill since its launch stateside, with weekly prescriptions exceeding 200,000. Sales of the pill hit 2.26 billion Danish krone (£261m) in the quarter to 31 March, beating analyst predictions.

Even so, the group’s adjusted net sales were down 10% for the quarter, and adjusted operating profit fell 15%.

It said adjusted sales could drop as much as 12% this year, but this marked an improvement from previous guidance of 13%.

Mike Doustdar, Novo’s cchief executive, said:

double quotation markWegovy is driving a strong start to 2026 for Novo Nordisk, led by the rapid adoption of Wegovy pill – the most efficacious GLP-1 tablet now used by more than one million patients since its January launch.

As the global momentum behind peptide-based therapies accelerates, Wegovy pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for what patients and physicians can expect.

The strong Wegovy performance, combined with continued growth in international operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit.

Chris Beauchamp, chief market analyst at IG, said:

double quotation markAfter the madness of the last three years it looks like Novo’s shares are returning to their longer-term trend – the euphoria that saw the shares reach such dizzying highs has entirely evaporated, but today’s numbers still point to a very healthy business and a long-term opportunity in Wegovy.

It might not have changed the world overnight, but it certainly marked a shift in treatments, a more consequential story in the long run, and one far more beneficial to sensible growth in the share price.

Share



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles